Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study
Viruses · 2024
DOI: 10.3390/v17010040 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Viruses, 2024. Verfasst von Lucio Boglione und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy. Hauptthemen laut MEDLINE: COVID-19, Hepatitis B, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The effects of a concomitant infection of hepatitis B virus (HBV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are still debated, with a recognized major risk of HBV reactivation during immune-suppressive treatments. The aim of this study was to determine the prevalence and predictive factors of HBV reactivation in a cohort of hospitalized patients with coronavirus disease 2019 (COVID-19) and a current or past hepatitis B infection. In a monocentric retrospective observational study, we enrolled all consecutive hospital admitted patients with COVID-19 pneumonia and a positive HBV serology (N = 84) in our Infectious Diseases Unit from April 2021 to December 2023. We identified 18 (21%) HBsAg-positive/anti-HBc-positive, 41 (49%) HBsAg-negative/anti-HBc-positive/anti-HBs-positive, and 25 (30%) HBsAg-negative/anti-HBc-positive/anti-HBs-negative subjects. The overall rate of hepatitis flare was 10.7%, without any HBsAg seroreversion, severe HBV reactivation, and/or need for new HBV antiviral therapy introduction. Systemic corticosteroid treatment for COVID-19 and baseline anti-HBsAg status were associated with this risk of HBV reactivation. In conclusion, the overall risk of hepatitis flares in hospitalized COVID-19 was reasonably low, with higher doses of corticosteroids treatment being the major risk factor for HBV reactivation, and anti-HBs-positive serological status as a protective element.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy.
- Laboratory of Molecular Virology, Maggiore della Carità Hospital, 28100 Novara, Italy.
- Clinical Biochemistry Laboratory, City of Health and Science University Hospital, 10126 Turin, Italy.
- Internal Medicine Unit, Maggiore della Carità Hospital, 28100 Novara, Italy.
ORCID-Profile: Mario Pirisi, Carlo Smirne
Zitieren
APA
Boglione, L., Crobu, M. G., Pirisi, M., & Smirne, C. (2024). Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study. Viruses. https://doi.org/10.3390/v17010040
Vancouver
Boglione L, Crobu MG, Pirisi M, Smirne C. Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study. Viruses. 2024. doi:10.3390/v17010040
BibTeX
@article{Boglione2024,
author = {Boglione, Lucio and Crobu, Maria Grazia and Pirisi, Mario and Smirne, Carlo},
title = {Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study},
journal = {Viruses},
year = {2024},
doi = {10.3390/v17010040}
}
EUVIMED